Bicycle Therapeutics (BCYC) Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BCYC shares.
View BCYC analyst ratings or view top-rated stocks.

11 Wall Street research analysts have issued 1 year price objectives for Bicycle Therapeutics' stock. Their BCYC share price forecasts range from $30.00 to $74.00. On average, they expect the company's share price to reach $53.20 in the next twelve months. This suggests a possible upside of 110.6% from the stock's current price.
View analysts price targets for BCYC or view top-rated stocks among Wall Street analysts.

Bicycle Therapeutics' stock was trading at $29.60 at the beginning of 2023. Since then, BCYC shares have decreased by 14.7% and is now trading at $25.26.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our BCYC earnings forecast.

Bicycle Therapeutics plc (NASDAQ:BCYC) announced its earnings results on Wednesday, November, 3rd. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.02. The firm earned $4.33 million during the quarter, compared to analysts' expectations of $5.29 million. Bicycle Therapeutics had a negative net margin of 801.45% and a negative trailing twelve-month return on equity of 44.57%.

ETFs with the largest weight of Bicycle Therapeutics (NASDAQ:BCYC) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), Horizon Kinetics Medical ETF (MEDX), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Harbor Disruptive Innovation ETF (INNO), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB) and

Based on aggregate information from My MarketBeat watchlists, some companies that other Bicycle Therapeutics investors own include Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Fulcrum Therapeutics (FULC), Mersana Therapeutics (MRSN), AbbVie (ABBV), Adverum Biotechnologies (ADVM), Agenus (AGEN), Applied Genetic Technologies (AGTC), Akero Therapeutics (AKRO) and Alector (ALEC).

(BCYC) raised $64 million in an initial public offering on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC."

Bicycle Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Candriam S.C.A. (6.12%), Sio Capital Management LLC (4.54%), Logos Global Management LP (3.52%), Armistice Capital LLC (3.45%), First Light Asset Management LLC (3.28%) and AXA S.A. (2.16%). Insiders that own company stock include Kate Bingham, Kevin Lee, Lee Kalowski, Michael Skynner, Nicholas Keen, Nigel Crockett, Pierre Legault, Plc Glaxosmithkline and Stephen B Alexander.
View institutional ownership trends.

Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BCYC stock can currently be purchased for approximately $25.26.

Bicycle Therapeutics (NASDAQ:BCYC) has a market capitalization of $758.81 million and generates $14.46 million in revenue each year. The company earns $-112,720,000.00 in net income (profit) each year or ($4.17) on an earnings per share basis.

The company employs 119 workers across the globe.

Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The official website for the company is www.bicycletherapeutics.com. The company can be reached via phone at 441223261503 or via email at david.borah@bicycletx.com.